In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jiangbo Launches Generic Of Astrazeneca's Plendil, Targeting 153 Million Hypertension Patients In China

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Nasdaq-listed Chinese pharma Jiangbo received approval from China's State FDA to manufacture Felodipine Sustained Release Tablets, a generic version of Plendil (felodipine)

You may also be interested in...



Novartis Renin Inhibitor Rasilez Approved In China For Hypertension

SHANGHAI - Novartis has received regulatory approval in China for Rasilez (aliskiren) for treatment of high blood pressure alone or as a combination therapy with other anti-hypertension drugs, the Swiss company announced July 20. Aliskiren is marketed as Tekturna in the U.S

Novartis Renin Inhibitor Rasilez Approved In China For Hypertension

SHANGHAI - Novartis has received regulatory approval in China for Rasilez (aliskiren) for treatment of high blood pressure alone or as a combination therapy with other anti-hypertension drugs, the Swiss company announced July 20. Aliskiren is marketed as Tekturna in the U.S

China Delays Implementation Of Essential Drugs List; Analysts Say List Has Less Impact Than Earlier Predicted

SHANGHAI - China's Ministry Of Health announced it will delay implementation of the Essential Drug List in 30 percent of government-controlled clinics until the end of March

Related Content

UsernamePublicRestriction

Register

SC075096

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel